Product Theaters & Non-CME Sessions


PDA is happy to announce the Product Theaters/Non-CME educational sessions that will take place at the Resort at Squaw Creek during our 73rd Annual Meeting. Food and beverage will be provided for attendees at all Product Theaters/Non-CME educational sessions.

*Please note that these are non-CME accredited sessions.


THURSDAY | August 19, 2021
11:45 am - 12:45 pm
Lunch & Product Theater*
Presented by Lilly

Taltz: See the Difference - An Overview of Long-Term Efficacy and Safety
Jennifer Soung, MD, Southern California Dermatology

This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session following the presentation.


THURSDAY | August 19, 2021
4:15 pm - 5:00 pm
Reception & Product Theater*
Presented by UCB

Your Next Move And Theirs: A Case-Based Approach for Evolving Patients With Psoriatic Disease
James Song, MD, North Sound Dermatology

Join your peers for a case-based program evaluating treatment options for patients with psoriatic disease.


FRIDAY | August 20, 2021
12:15 pm - 1:15 pm
Lunch & Product Theater*
Presented by Sanofi Genzyme and Regeneron

A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis
James Q. Del Rosso, Del Rosso Dermatology Research

Learn more about a treatment that may help your appropriate atopic dermatitis patients with uncontrolled moderate-to-severe atopic dermatitis.


SATURDAY | August 21, 2021
12:15 pm - 1:15 pm
Lunch & Product Theater*
Presented by AbbVie

Seeking Clearance Exploring SKYRIZI for Adults with Moderate to Severe Plaque Psoriasis
Raja Sivamani, MD, University of California, Davis

The presentation provides a review of the UltIMMa-1 and UltIMMa-2, and IMMerge trials for SKYRIZI for adults with Moderate to Severe Plaque Psoriasis.


SUNDAY | August 22, 2021
8:00 am - 8:45 am
Breakfast & Product Theater*
Presented by Janssen

The First and Only IL-23 Inhibitor Approved for Adults With Moderate to Severe Plaque Psoriasis and Adults With Active Psoriatic Arthritis
John Koo, MD, University of California, San Francisco